secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0001104659-24-049988
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent BioPharma appoints Kristine Peterson to Board of Directors
-------------------------------------------------------------------

- Appointment effective April 20, 2024; Peterson to serve as Class III Director until 2027 annual meeting.
- Peterson brings over 30 years' experience; former CEO of Valeritas and executive at J&J and Bristol-Myers Squibb.
- Receives non‑employee director compensation: annual cash retainer of $45,000 and stock option with $235,000 grant date fair value.
- Option vests one year from grant date (April 22, 2024); no related transactions or family relations disclosed.
- Board determined she is independent under Nasdaq rules; no committee assignments yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924049988/0001104659-24-049988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924049988/tm2412347d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-049988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer